TABLE 5

Susceptibility results for clinical and recombinant isolates carrying genes encoding the new β-lactamase GES-22 and VIM-35a

Antimicrobial agentMIC (μg/ml)
GES-22-producing A. baumannii clinical isolateE. coli TOP10 pZERO Blunt (blaGES-22)E. coli TOP10 pZERO Blunt (blaGES-11)E. coli TOP10bVIM-35-producing K. oxytoca clinical isolateE. coli XLGold PCRScript (blaVIM-35)E. coli XLGold PCRScript (blaVIM-1)E. coli XLGold PCRScript
Doripenem>8≤0.06≤0.06≤0.06>811≤0.06
Imipenem>320.250.250.25>32420.25
Meropenem>32≤0.06≤0.06≤0.06160.250.25≤0.06
Cefoxitin>256444>256>256>2564
Ceftriaxone>25616256≤0.2564832≤0.25
Ceftazidime>256>256>256≤0.12>25612864≤0.12
Cefepime>2561616≤0.126424≤0.12
Aztreonam>16>16>16≤0.1280.250.25≤0.12
Ampicillin>256>256>2562>256>256>2564
Ampicillin-sulbactam>3232328>32>32>328
Piperacillin-tazobactam>25632>25686416>2562
Amikacin8c16
Tobramycin4>16
Gentamicin≤12
Ciprofloxacin>4>4
Tigecycline0.51
Colistin0.50.5
  • a The susceptibility profiles of recombinant strains carrying new enzymes were compared to those of recombinant strains carrying the GES-11 and VIM-1 genes that displayed the closest homology.

  • b Only recipient host was tested, since pZERO Blunt is a suicidal plasmid.

  • c —, not tested.